(1996) Inflammation, free radicals and antioxidants
Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target
Simultaneously, focus should be placed on precision medicine and the development of targeted therapies (e.g., antioxidants targeting mitochondria), or on establishing personalized treatment plans based on specific OS biomarkers (such as 8-OHdG and MDA levels) in patient circulation or tissues
These issues can lead to symptoms like: Bloating (especially after meals) Diarrhoea or constipation Excessive gas or frequent burping Nausea or feeling full quickly Abdominal pain or cramping Its estimated in people with IBS, SIBO may contribute to symptoms in around 38% of cases
GLP-1s as a class took off when semaglutide was approved for chronic weight management in 2021
Your cardiologist can help you evaluate the potential benefits and risks based on your heart health, medical history, and weight loss goals